AC Immune SA reported a net income of CHF 5,503 thousand, or CHF 0.06 per share, for the third quarter ended September 30, 2024. This marks a significant improvement from a net loss of CHF 15,143 thousand in the same period of 2023. The company's total revenue for Q3 2024 was CHF 25,485 thousand, compared to no revenue in Q3 2023.
The positive financial performance was bolstered by a CHF 24.6 million milestone payment from Janssen. This payment was triggered by rapid prescreening rates in the Phase 2b ReTain trial of JNJ-2056 (ACI-35.030), an anti-phospho-Tau active immunotherapy.
Further supporting its pipeline, JNJ-2056 also received Fast Track designation from the U.S. FDA, an important recognition of its potential to address unmet medical needs. As of September 30, 2024, AC Immune held cash resources of CHF 157.9 million, including the recently triggered milestone payment, providing financial stability for ongoing operations.
The company also confirmed that its ACI-7104.056 VacSYn Phase 2 trial for Parkinson’s disease is on track to report interim safety and immunogenicity data. This progress in its clinical pipeline, combined with the strong financial results, positions AC Immune for continued development in neurodegenerative diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.